Good news! Zhongsheng pharmaceutical zsp1602 won Korean patent

Last night, Guangdong Zhongsheng Pharmaceutical Co., Ltd announced that it had received a patent certificate issued by the Korean Intellectual Property Office The following is the full text of the announcement: Recently, Guangdong Zhongsheng Pharmaceutical Co., Ltd (hereinafter referred to as "the company") received a patent certificate issued by the Korean Intellectual Property Office The details are as follows: Patent name: smo 억 pressure  pressure  (quinoline derivative as SMO inhibitor) patent No.: 10-1910724 patent application date: March 16, 2015 patentee: Guangdong Zhongsheng Pharmaceutical Co., Ltd patent term: 20 years from the date of application The patent is a compound patent of zsp1602 project, which is jointly developed by the company and Shanghai yaomingkant new drug development Co., Ltd for the treatment of small cell lung cancer, gastric cancer, esophageal cancer and other malignant tumors It belongs to the core patent of the project At present, the core patent of zsp1602 project compound has been granted by South Korea, Canada, Israel, New Zealand, Japan and other countries The global intellectual property protection system of zsp1602 has been gradually improved According to the pharmaceutical intelligence data, at present, only Guangdong Zhongsheng pharmaceutical has registered and applied for clinical application, and has been approved for clinical application, and has started phase I clinical work.